Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Open accessThe DOI matches its Crossref record; 265 of the 268 references it cites were found in a registry or an index.
Abstract
The blood–brain barrier (BBB) plays a vital role in the protection and maintenance of homeostasis in the brain. In this way, it is an interesting target as an interface for various types of drug delivery, specifically in the context of the treatment of several neuropathological conditions where the therapeutic agents cannot cross the BBB. Drug toxicity and on-target specificity are among some of the limitations associated with current neurotherapeutics. In recent years, advances in nanodrug delivery have enabled the carrier system containing the active therapeutic drug to target the signaling pathways and pathophysiology that are closely linked to central nervous system (CNS) disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis (MS), brain tumor, epilepsy, ischemic stroke, and neurodegeneration. At present, among the nano formulations, solid lipid nanoparticles (SLNs) have emerged as a putative drug carrier system that can deliver the active therapeutics (drug-loaded SLNs) across the BBB at the target site of the brain, offering a novel approach with controlled drug delivery, longer circulation time, target specificity, and higher efficacy, and more importantly, reducing toxicity in a biomimetic way. This paper highlights the synthesis and application of SLNs as a novel nontoxic formulation strategy to carry CNS drugs across the BBB to improve the use of therapeutics agents in treating major neurological disorders in future clinics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, SLNs utilize receptor-mediated and adsorptive-mediated transcytosis to cross the BBB and enable sustained drug release [74].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [74]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SLNs can effectively transport drugs across the BBB, enabling the delivery of compounds that are otherwise impermeable [74].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595 · cited 1×
“Besides this, the endothelial cells of the BBB also restrict active molecules from entering the brain by limiting pinocytic activity [83–85].”
Solid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759 · cited 3×
“These features make SLNs advantageous for production on a large industrial scale [43].”
InfluentialSacco, R. L., Kasner, S. E., Broderick, J. P., Caplan, L. R., Connors, J. J. (., Culebras, A., Elkind, M. S. V., George, M. G., Hamdan, A. D., Higashida, R. T., et al. (2013) · Stroke · doi:10.1161/str.0b013e318296aeca · Cited by 3,569 · cited 1×
“There are several types of ischemic strokes, such as lacunar, cardioembolic, and cryptogenic strokes, and hemorrhagic strokes [259].”
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Solid lipid nanoparticles Production, characterization and applications
Mehnert, W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00105-3 · Cited by 3,150 · cited 2×
“SLNs can also be synthesized by ultrasonication [120,170,173] (Figure 7) in an easily assessable way, to overcome the limitations of high-shear homogenization.”
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969 · cited 1×
“The essential neurovascular unit cell types that contribute to the functionality of the BBB are endothelial cell adhesion molecules, pericytes, smooth muscle cells, astrocytes, and micro glia, etc., which form the BBB, a complex barrier unit [13–16].”
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261 · cited 1×
“Besides this, the endothelial cells of the BBB also restrict active molecules from entering the brain by limiting pinocytic activity [83–85].”
The Role of Glutamate Neurotoxicity in Hypoxic-Ischemic Neuronal Death
Choi, D. W., & Rothman, S. M. (1990) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.13.030190.001131 · Cited by 2,223
Animal Communication: When I’m Calling You, Will You Answer Too?
Vickers, N. J. (2017) · Current Biology · doi:10.1016/j.cub.2017.05.064 · Cited by 2,210
Research works printed but not linked: 8
- Dingler A. Feste Lipid-Nanopartikel als Kolloidale Wirkstoffträgersysteme zur Dermalen Applikation Ph.D. Thesis Freie Universität Berlin Berlin, Germany 1998
- Müller R. Schwarz C. Zur Mühlen A. Mehnert W. Incorporation of lipophilic drugs and drug release profiles of solid lipid nanoparticles (SLN) Proceedings of International Symposium on Controlled Release of Bioactive Materials Nice, France 27–30 June 1994 146 147 · DOI · Paper page
- Zur Mühlen A. Mehnert W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles Pharmazie 1998 53 552 555 9704911
- zur Muhlen A. Feste Lipid Nanopartikel mit Prolongierter Wirkstoffliberation: Herstellung, Langzeitstabilität, Charakterisierung, Freisetzungsverhalten und Mechanismen Ph.D. Thesis Free University of Berlin Berlin, Germany 1996
- Meyer W. Wettkampf und Spiel in den Miniaturen der Manessischen Liederhandschrift Stadion 1988 14 1 48
- Nelluri S. Felix J. Sathesh K. Formulation and evaluation of galantamine nanoparticles for neurological disorders Int. J. Pharm. Chem. Biol. Sci. 2015 5 63 70
- Özdemir Y.G. Pehlivan S.B. Sekerdag E. Nanotechnology Methods for Neurological Diseases and Brain Tumors: Drug Delivery Across the Blood–Brain Barrier Academic Press Cambridge, MA, USA 2017
- Duarte A.M.G. Resveratrol and Grape’s Extract-Loaded Solid Lipid Nanoparticles for the Treatment of Parkinson’s and Alzheimer’s Diseases Master’s Thesis Faculty of Engineering of University of Porto Porto, Portugal 2015
Cited by
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review
Khan, M. I., Hossain, M. I., Hossain, M. K., Rubel, M. H. K., Hossain, K. M., Mahfuz, A. M. U. B., & Anik, M. I. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00002 · Cited by 370
Review on the Scale-Up Methods for the Preparation of Solid Lipid Nanoparticles
Khairnar, S. V., Pagare, P., Thakre, A., Nambiar, A. R., Junnuthula, V., Abraham, M. C., Kolimi, P., Nyavanandi, D., & Dyawanapelly, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091886 · Cited by 263
“The spray-drying technique procedure is reproduced from [43].”
MethodAkombaetwa, N., Ilangala, A. B., Thom, L., Memvanga, P. B., Witika, B. A., & Buya, A. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020656 · Cited by 215
Correia, A. C., Monteiro, A. R., Silva, R., Moreira, J. N., Sousa Lobo, J. M., & Silva, A. C. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114485 · Cited by 206
Subroto, E., Andoyo, R., & Indiarto, R. (2023) · Antioxidants · doi:10.3390/antiox12030633 · Cited by 160
Mohammed, H. A., Khan, R. A., Singh, V., Yusuf, M., Akhtar, N., Sulaiman, G. M., Albukhaty, S., Abdellatif, A. A. H., Khan, M., Mohammed, S. A. A., et al. (2023) · Nanotechnology Reviews · doi:10.1515/ntrev-2022-0517 · Cited by 125
Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery
Maher, R., Moreno-Borrallo, A., Jindal, D., Mai, B. T., Ruiz‐Hernández, E., & Harkin, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030746 · Cited by 116
“PEGylation of NPs for CNS drug delivery is common and is reported to improve the circulation time, biocompatibility, and brain uptake, even in pathological conditions [9,10,37,38].”
BackgroundDighe, S., Jog, S., Momin, M. M., Sawarkar, S. P., & Omri, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010058 · Cited by 106
“Solid lipid nanoparticles, as the first generation of lipid nanocarriers, were designed to surmount the limitations of liposomes by utilizing lipids to replace the aqueous core, thereby preventing active drug interactions [112].”
BackgroundSolid Lipid Nanoparticles: Multitasking Nano-Carriers for Cancer Treatment
German-Cortés, J., Vilar-Hernández, M., Rafael, D. F. D. S., Abasolo, I., & Andrade, F. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030831 · Cited by 94
“Also, the main advantages of SLNs over liposomes rely on the higher stability and loading capacity of hydrophobic drugs [7,10].”
BackgroundMethodNanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer’s disease
Taliyan, R., Kakoty, V., Sarathlal, K. C., Kharavtekar, S. S., Karennanavar, C. R., Choudhary, Y. K., Singhvi, G., Riadi, Y., Dubey, S. K., & Kesharwani, P. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.044 · Cited by 80
Self-citationOliyaei, N., Moosavi‐Nasab, M., Tanideh, N., & Iraji, A. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.11.018 · Cited by 85
“SLNs are usually fabricated by biodegradable lipids with a mean particle size of 50–1000 nm (Satapathy and Yen, 2021; Santonocito et al., 2021).”
BackgroundZhao, C., Zhu, X., Tan, J., Mei, C., Cai, X., & Kong, F. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116113 · Cited by 94
Cai, X., Drummond, C. J., Zhai, J., & Tran, N. L. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202404234 · Cited by 77
Lipid Nanoparticles Deliver mRNA to the Brain after an Intracerebral Injection
Tuma, J., Chen, Y.-J., Collins, M. G., Paul, A., Li, J., Han, H., Sharma, R., Murthy, N., & Lee, H. Y. (2023) · Biochemistry · doi:10.1021/acs.biochem.3c00371 · Cited by 65
Jiao, Y., Yang, L., Wang, R., Song, G., Fu, J., Wang, J., Gao, N., & Wang, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121611 · Cited by 63
“…proteins on the cell membrane [184,185], thereby offering a novel avenue for drug delivery targeting the BBB. Solid lipid nanoparticles (SLNs) [186] represent a promising therapeutic tool for targeted drug delivery, with the potential to overcome the barriers posed by the BBB through the…”
Self-citationLayunta, E., Buey, B., Mesonero, J. E., & Latorre, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.748254 · Cited by 73
Kochman, U., Sitka, H., Kuźniar, J., Czaja, M., Kozubek, P., Beszłej, J. A., & Leszek, J. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05417-z · Cited by 60
Khan, M. S., Mohapatra, S., Gupta, V., Ali, A., Naseef, P. P., Kuruniyan, M. S., Alshadidi, A. A. F., Alam, M. S., Mirza, M. A., & Iqbal, Z. (2023) · Membranes · doi:10.3390/membranes13030343 · Cited by 66
“Further, a high load of SLN results in a higher concentration gradient at the brain capillary, resulting in enhanced transport across the brain endothelium following endocytosis and drug release [91].”
BackgroundRazavi, Z. S., Alizadeh, S. S., Razavi, F. S., Souri, M., & Soltani, M. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125186 · Cited by 65
Advances in nanotechnology versus stem cell therapy for the theranostics of Huntington's disease
Channa, G. M., Hassan, D., Zeeshan, M., Ruiz-Pulido, G., Ebrahimi, N., Mobashar, A., Pourmadadi, M., Rahdar, A., Sargazi, S., Fathi‐karkan, S., et al. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104774 · Cited by 61
The Importance of Phosphoinositide 3-Kinase in Neuroinflammation
Wright, B., King, S. P., & Suphioglu, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111638 · Cited by 60
“…PI3K inhibitors across the BBB. Lipid-based nanoparticles (liposomes, solid lipid nanoparticles) encapsulating PI3K inhibitors improve solubility and circulation time, whilst modifying the surface with ligands, such as transferrin or lactoferrin, enables receptor-mediated BBB penetration [195,196].”
BackgroundPrecision targeting of the CNS: recent progress in brain-directed nanodrug delivery
Senanayake, D., Yapa, P. N., Dabare, S., & Munaweera, I. (2025) · RSC Advances · doi:10.1039/d5ra03578c · Cited by 67
“33 Polymeric NPs have successfully passed preclinical evaluations, yet their clinical use for brain drug delivery remains restricted because only a few have started phase I trials, and none focus on brain diseases.”
Shivananjegowda, M. G., Hani, U., Osmani, R. A. M., Alamri, A. H., Ghazwani, M., Alhamhoom, Y., Rahamathulla, M., Paranthaman, S., Gowda, D. V., & Siddiqua, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010221 · Cited by 55
Susa, F., Arpicco, S., Pirri, C. F., & Limongi, T. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070849 · Cited by 59
“However, SLNs also have some drawbacks, such as poor drug loading due to the limited space in the organized solid lipid core and the possible interaction of the drug with the lipid matrix, resulting in a failure of the formulation [157,158].”
BackgroundLipid-based nanocarriers for ocular drug delivery: An updated review
Das, B., Nayak, A. K., & Mallick, S. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103780 · Cited by 53
Overview of Solid Lipid Nanoparticles in Breast Cancer Therapy
Mo, K., Kim, A., Choe, S., Shin, M., & Yoon, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082065 · Cited by 55
Rodrigues, R. O., Shin, S.-R., & Bañobre-López, M. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02720-0 · Cited by 44
“Among those proteins are glucose transporter type 1 (GLUT-1) and large neutral amino acid transporters (LAT), playing a crucial role in the delivery of several molecules to the brain [49].”
BackgroundInfluentialTincu, C.-E., Andrițoiu, C. V., Popa, M., & Ochiuz, L. (2023) · Polymers · doi:10.3390/polym15193969 · Cited by 50
“Another disadvantage is the burst effect caused by erosion that usually occurs with these formulations, which can cause toxicity in the body due to the drug dose being too high [15].”
BackgroundLipid-based Nanoparticles: Strategy for Targeted Cancer Therapy
Chauhan, A. S., Chand, P., & Parashar, T. (2025) · BIO Integration · doi:10.15212/bioi-2024-0107 · Cited by 54
“SLNs also offer an advantage of controlled drug release, which is particularly beneficial for maintaining therapeutic drug concentrations and decreasing administration frequency [63].”
Carbon nanotubes in brain targeted drug delivery: A comprehensive review
Das, S., Roy, S., Dinda, S. C., Bose, A., Mahapatra, C., Basu, B., & Prajapati, B. G. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102206 · Cited by 46
Lipid-engineered nanotherapeutics for cancer management
Fernandez-Fernandez, A., Manchanda, R., & Kumari, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1125093 · Cited by 44
“SLNs have also shown promising results for brain tumor drug delivery, and may demonstrate an enhanced ability to cross the blood-brain barrier (Blasi et al., 2007; Gastaldi et al., 2014; Satapathy et al., 2021).”
BackgroundMovahedpour, A., Taghvaeefar, R., Asadi‐Pooya, A. A., Karami, Y., Tavasolian, R., Khatami, S. H., Fard, E. S., Taghvimi, S., Karami, N., Jaberi, K. R., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14355 · Cited by 43
“38,43”
Nanomaterials as drug delivery agents for overcoming the blood-brain barrier: A comprehensive review
Kulkarni, M., Patel, K., Patel, A. K., Patel, S., Desai, J. L., Patel, M. M., Shah, U., Patel, A. D., & Solanki, N. D. (2023) · ADMET & DMPK · doi:10.5599/admet.2043 · Cited by 74
“This includes assessing potential neuronal cell death and disruptions in neurodevelopment caused by nanomaterial exposure [178].”
BackgroundMilić, J., Đoković, J. B., Nikolić, I., Mitrović, J. R., Pantelić, I., Savic, S. D., & Savić, M. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020443 · Cited by 41
“Intranasal administration, praised for its ability to deliver drugs directly to the brain while bypassing the BBB, is highly dependent on the nature of the nasal mucosa and potential drug interactions [20].”
BackgroundGhosh, A., Khanam, N., & Nath, D. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111084 · Cited by 39
Harnessing role of sesamol and its nanoformulations against neurodegenerative diseases
Singh, N., Vishwas, S., Kaur, A., Kaur, H., Kakoty, V., Khursheed, R., Chaitanya, M., Babu, M. R., Awasthi, A., Corrie, L., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115512 · Cited by 38
“These are safe, cheap, and lipid-based (solid, such as fatty acid, waxes, etc.) carrier systems [88].”
Posterity of nanoscience as lipid nanosystems for Alzheimer's disease regression
Naser, S. S., Singh, D., Preetam, S., Kishore, S., Kumar, L., Nandi, A., Simnani, F. Z., Choudhury, A., Sinha, A., Mishra, Y. K., et al. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100701 · Cited by 43
“SLNs for AD drug delivery (a) SLN-loaded drugs transport mechanism via BBB, (b) Apolipoprotein-targeted SLNs for CNS targeting [88].”
BackgroundFar, B. F., Safaei, M., Pourmolaei, A., AdibAmini, S., Shirdel, S., Shirdel, S., Emadi, R., & Kaushik, A. K. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c00112 · Cited by 40
Bernoud‐Hubac, N., Van, A. L., Lazar, A. N., & Lagarde, M. (2024) · Antioxidants · doi:10.3390/antiox13060634 · Cited by 39
Chen, X., Luo, X., Yin, W., Cui, W., He, Y., Tian, T., & Lin, Y. (2025) · ACS Nano · doi:10.1021/acsnano.5c03945 · Cited by 40
Song, Q., Li, J., Li, T., & Li, H. (2024) · Advanced Science · doi:10.1002/advs.202403473 · Cited by 43
Sarkhel, S., Shuvo, S. M., Ansari, M. A., Mondal, S., Kapat, P., Ghosh, A., Sarkar, T., Biswas, R., Atanase, L. I., & Cărăuleanu, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121572 · Cited by 48
Recent Updates on Applications of Lipid-Based Nanoparticles for Site- Specific Drug Delivery
Agrawal, S., Garg, A., & Varshney, V. (2022) · Pharmaceutical Nanotechnology · doi:10.2174/2211738510666220304111848 · Cited by 33
Ligands for oral delivery of peptides across the blood-brain-barrier
Gailani, M. A., Liu, M., & Wen, J. (2022) · Acta Materia Medica · doi:10.15212/amm-2021-0007 · Cited by 37
“Solid lipid nanoparticles SLNs (Figure 3) are a colloidal drug delivery system with a spherical solid lipid matrix between 10 and 1,000 nm, which are dispersed in aqueous solution [128, 129].”
BackgroundNanoparticles loaded with natural medicines for the treatment of Alzheimer’s disease
Liu, N., Ruan, J., Li, H., & Fu, J.-H. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1112435 · Cited by 40
Recent advancements in nanoparticle-mediated approaches for restoration of multiple sclerosis
Rahiman, N., Mohammadi, M., Alavizadeh, S. H., Arabi, L., Badiee, A., & Jaafari, M. R. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.009 · Cited by 30
Kumar, H., Chakrabarti, A., Sarma, P., Modi, M., Banerjee, D., Radotra, B. D., Bhatia, A., & Medhi, B. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106348 · Cited by 34
Cai, Y., Fan, K., Lin, J., Ma, L., & Li, F. (2022) · Micromachines · doi:10.3390/mi14010112 · Cited by 29
Advancing lipid nanoparticles: A pioneering technology in cosmetic and dermatological treatments
Pareek, A., Kapoor, D. U., Yadav, S. K., Rashid, S., Fareed, M., Akhter, M. S., Muteeb, G., Gupta, M. M., & Prajapati, B. G. (2024) · Colloids and Interface Science Communications · doi:10.1016/j.colcom.2024.100814 · Cited by 37
Olawade, D. B., Rashad, I., Egbon, E., Teke, J., Ovsepian, S. V., & Boussios, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104929 · Cited by 37
Suriyaamporn, P., Pamornpathomkul, B., Wongprayoon, P., Rojanarata, T., Ngawhirunpat, T., & Opanasopit, P. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e123549 · Cited by 29
“…in this study was a potential formulation for delivering therapeutics across the BBB, featuring appropriate spherical shape, particle size in the nanometer range, the lowest polydispersity index (PDI), suitable charge, and high lipophilicity (log P 3.87) (Lo et al. 2021; Satapathy et al. 2021).”
BackgroundInfluentialRecent Advances in RNA Therapy and Its Carriers to Treat the Single-Gene Neurological Disorders
Lee, M., Lee, I., & Wang, K. (2022) · Biomedicines · doi:10.3390/biomedicines10010158 · Cited by 28
“The advantages of SLNs include maximum drug bioavailability after administration, good control release kinetics, better tissue targeting, reduced immune responses, the ability to penetrate the BBB with little neurotoxicity, the ability to deliver both small molecules and biomolecules, adequate drug loading, good patie…”
BackgroundAdvances and Challenges in Nano-Delivery Systems for Glioblastoma Treatment: A Comprehensive Review
Wang, K., Sun, J., Zhao, H., Wang, F., Zhang, X., Zhao, X., Li, Z., Zhang, L., Ren, H. J., & Guo, B. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s531451 · Cited by 36
Solid Lipid Nanoparticles: Peculiar Strategy to Deliver Bio-Proactive Molecules
Minocha, N., Sharma, N., Verma, R., Kaushik, D. K., & Pandey, P. (2022) · Recent Patents on Nanotechnology · doi:10.2174/1872210516666220317143351 · Cited by 27
Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics
Cerqueira, M. C., Belmonte‐Reche, E., Gallo, J., Baltazar, F., & Bañobre‐López, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030506 · Cited by 28
Development of solid lipid nanoparticles-loaded drugs in parasitic diseases
Nemati, S., Mottaghi, M., Karami, P., & Mirjalali, H. (2024) · Discover Nano · doi:10.1186/s11671-023-03955-w · Cited by 33
Agrawal, Y. O., Husain, M., Patil, K. D., Sodgir, V., Patil, T. S., Agnihotri, V. V., Mahajan, H. S., Sharma, C., Ojha, S. K., & Goyal, S. N. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113429 · Cited by 24
Current and future directions of drug delivery for the treatment of mental illnesses
Brewster, P. R., Bari, S. M. I., Walker, G. M., & Werfel, T. A. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114824 · Cited by 30
Lamptey, R. N. L., Sun, C., Layek, B., & Singh, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032213 · Cited by 26
“Due to their favorable cell membrane permeabilities, SLNs are proposed as an effective way to cross the BBB, thus a potentially effective tool for use in NH management [169,172,173].”
BackgroundGrosso, C., Silva, A., Delerue-Matos, C. M., & Barroso, M. F. (2023) · Pharmaceuticals · doi:10.3390/ph16121721 · Cited by 26
“Compared to liposomes and polymeric nanoparticles, SLNs safeguard better the encapsulated drug from biochemical degradation due to the solid lipid nature of their core instead of the water-soluble core of other types of nanoparticles [76].”
BackgroundPolymer Vesicles and Lipid Nanoparticles
Luo, Y., Cook, A. B., Abdelmohsen, L. K. E. A., & van Hest, J. C. M. (2024) · Annual Review of Materials Research · doi:10.1146/annurev-matsci-080222-105636 · Cited by 24
Cell type-targeting nanoparticles in treating central nervous system diseases: Challenges and hopes
Guo, S., & Yi, C. (2023) · Nanotechnology Reviews · doi:10.1515/ntrev-2023-0158 · Cited by 25
Schwinghamer, K., & Siahaan, T. (2023) · Journal of Nanotheranostics · doi:10.3390/jnt4040020 · Cited by 17
Castellani, S., Iaconisi, G. N., Tripaldi, F., Porcelli, V., Trapani, A., Messina, E., Guerra, L., Franco, C. D., Maruccio, G., Monteduro, A. G., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081048 · Cited by 25
“In particular, SLNs are extensively used to improve the formulation of hydrophobic drugs, but, relevantly, selected formulation protocols also allow hydrophilic drug substances to be encapsulated in these nanocarriers [23].”
BackgroundAldawsari, H. M., Badr-Eldin, S. M., Assiri, N. Y., Alhakamy, N. A., Privitera, A., Caraci, F., & Caruso, G. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2110996 · Cited by 22
“…endothelial cell receptors via induction of receptor-mediated transcytosis (Qiao et al., 2012; Pulgar, 2018), while SA targets the brain via the interaction with the negative charges existing on the BBB (Bors & Erdő, 2019; Satapathy et al., 2021), resulting in adsorptive-mediated endocytosis.”
BackgroundDrug delivery to the brain – lipid nanoparticles-based approach
Gugleva, V., & Andonova, V. (2023) · Pharmacia · doi:10.3897/pharmacia.70.e98838 · Cited by 24
Lynch, M. J., & Gobbo, O. L. (2021) · Nanomaterials · doi:10.3390/nano11102632 · Cited by 20
“chemotherapeutics such as doxorubicin (DOXIL), none have been approved to date for the treatment of CNS disorders [230], which is disappointing given the obviated advanatages of such nanocarriers that are capable of self-assembly and modularity with surfactant coatings to generate “niosomes” [18].”
BackgroundMetwaly, H. H., Fathy, S. A., Moneim, M. M. A., Emam, M. A., Soliman, A. F., El‐Naggar, M. E., Omara, E. A. A., & El‐Bana, M. A. (2021) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2021.1998275 · Cited by 19
“Furthermore, Satapathy et al. (2021) showed that SLNs can deliver the active drug contents to specific tissues in a controlled and sustained manner.”
BackgroundKanojia, N., Thapa, K., Kaur, G., Sharma, A., Puri, V., & Verma, N. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.104074 · Cited by 21
Ribeiro, J., Lopes, I., & Gomes, A. C. (2023) · Molecules · doi:10.3390/molecules28166015 · Cited by 22
RNA Combined with Nanoformulation to Advance Therapeutic Technologies
Lima, E. S., dos Santos, D., Souza, A. L., de Macedo, M. E. O., Bandeira, M. E., Silva, S. S., Fiuza, B. S. D., Rocha, V. P. C., Fonseca, L. M. D. S., Nunes, D. D. G., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16121634 · Cited by 21
“Furthermore, producing SLNs on a large scale is simple, and they are sterilizable [101,105].”
BackgroundMajumdar, A. G., Pany, B., Parua, S. S., Mukherjee, D., Panda, A., Mohanty, M., Das, B. B., Si, S., & Mohanty, P. S. (2024) · BioNanoScience · doi:10.1007/s12668-024-01577-9 · Cited by 22
“Different drug delivery systems including liposomes [92], polymeric nanoparticles [93, 94], lipid-based nanoparticles (SLNs, NLCs) [95, 96], and dendrimers [97] have gained significant attention in recent years due to their huge potential in improving drug stability, solubility, and targeting…”
Tiwary, P., Oswal, K., Varghese, R., Peri, R. V., & Gupta, P. K. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00109a · Cited by 22
New Strategies for Stroke Therapy: Nanoencapsulated Neuroglobin
Blanco, S., Martínez‐Lara, E., Siles, E., & Peinado, M. Á. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081737 · Cited by 22
“Regarding their ability to cross the BBB, their advantages as a strategy for brain drug delivery (longer circulation time, higher efficacy, reduced toxicity, site-specific targeted delivery via receptor-mediated transcytosis across brain capillary endothelial cells) overcome their limitations (smaller drug payload, st…”
BackgroundGupta, A., Jadhav, S. R., Colaco, V., Saha, M., Ghosh, A., Sreedevi, A., Datta, D., Hebbar, S., Moorkoth, S., Ligade, V. S., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125562 · Cited by 19
Melatonin and the nervous system: nanomedicine perspectives
Luo, F., Deng, Y., Angelov, B., & Angelova, A. (2025) · Biomaterials Science · doi:10.1039/d4bm01609b · Cited by 18
Fù, Y., Shi, C., Li, X., Wen, T., Wu, Q., Zhang, A., Hu, P., Wu, C., Pan, X., Huang, Z., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010169 · Cited by 18
“Due to the simple production process, high biocompatibility, and excellent drug-loading ability, SLNs are promising for clinical translation [33].”
BackgroundFighting Epilepsy with Nanomedicines—Is This the Right Weapon?
Matias, M., Santos, A. O., Silvestre, S., & Alves, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020306 · Cited by 22
“Both hydrophilic and hydrophobic agents can be dispersed in the solid hydrophobic lipid core [76].”
BackgroundLiposomal Nanomaterials: A Rising Star in Glioma Treatment
Gan, Y., Yu, Y., Xu, H., & Piao, H. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s470478 · Cited by 21
“114,115 116–119 However, there are no reports on the study of sphingosomes to cross the BBB and treat glioma up to now.”
BackgroundGe, Y., Xu, X., Cao, M., Liu, B., Wang, Y., Liao, P., Wang, J., Chen, Y., Yuan, H., & Chen, G. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070929 · Cited by 18
Self-citationEngendered nanoparticles for treatment of brain tumors
Soleymani, S., Asgari, K., Mobarakshahi, A., Aghaeipour, A., Doroudian, M., Soezi, M., Beladi, A., & MacLoughlin, R. J. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.053069 · Cited by 19
Peptide-based inhibitors and nanoparticles: Emerging therapeutics for Alzheimer’s disease
Mojarad-Jabali, S., & Roh, K. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125055 · Cited by 17
Singh, S., Hema, Sharma, N., Sachdeva, M., Behl, T., Zahoor, I., Fuloria, N. K., Sekar, M., Fuloria, S., Subramaniyan, V., et al. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-22830-2 · Cited by 24
Satpathy, B., Rajwar, T. K., Mishra, A. K., Saha, I., Rai, V. K., Sahoo, R. K., Halder, J., Mahanty, R., Manoharadas, S., Al‐Tamimi, J., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05137-4 · Cited by 20
“It can help in the permeation of bioactive compounds across BBB and target the brain site [35].”
Javid‐Naderi, M. J., & Shaegh, S. A. M. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100399 · Cited by 49
“The delivery of drugs across the blood-brain barrier (BBB) is a significant obstacle in the management of neurological disorders, and SLNs can be utilized to address this challenge (Satapathy et al., 2021).”
Marinelli, L., Dimmito, M. P., Cacciatore, I., Toto, E. C., Rienzo, A. D., Palmerio, F., Puca, V., Filippo, E. S. D., Fulle, S., & Stefano, A. D. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105097 · Cited by 21
Helmy, W. A., Ragab, T. I. M., Salama, B. M., Basha, M., Shamma, R. N., El‐Rahman, S. S. A., & Shawky, H. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.12.279 · Cited by 18
“…delivery systems during the last two decades, driven by the prohibitive cost of developing new drug entities, the discovery of new polymeric materials suitable for prolonging drug release, and the improvement in therapeutic efficiency and safety demonstrated by these delivery systems [23 – 26].”
BackgroundTheoretical and applied concepts of nanocarriers for the treatment of Parkinson's diseases
Bhosale, A., Paul, G., Mazahir, F., & Yadav, A. K. (2022) · OpenNano · doi:10.1016/j.onano.2022.100111 · Cited by 17
Amyloid –β pathology in Alzheimer’s disease: A nano delivery approach
Meghana, G. S., Gowda, D., Chidambaram, S. B., & Osmani, R. A. M. (2023) · Vibrational Spectroscopy · doi:10.1016/j.vibspec.2023.103510 · Cited by 17
Rafe, M. R. (2023) · Nanotheranostics · doi:10.7150/ntno.88849 · Cited by 18
“This new strategy offers controlled drug delivery, a longer circulation time, higher target specificity, and efficacy [20].”
Nanoparticles assisted drug delivery for effective management of Glioblastoma
Damani, M., Nilawar, N., Momin, M. M., Ningthoujam, R. S., & Khan, T. A. (2025) · Next Nanotechnology · doi:10.1016/j.nxnano.2025.100137 · Cited by 18
Suhandi, C., Wilar, G., Mohammed, A. F. A., Mahmoud, S. A., Muchtaridi, M., Shamsuddin, S., Safuan, S., Lesmana, R., Hasan, N., Zulhendri, F., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s525243 · Cited by 21
“60,61 As a next-generation lipid-based nanocarrier, NLC offer a superior alternative by incorporating liquid lipids into the matrix.”
Golbek, T. W., Okur, H. İ., Kulik, S. P., Dedic, J., Roke, S., & Weidner, T. (2023) · Langmuir · doi:10.1021/acs.langmuir.3c00276 · Cited by 15
Technological strategies for the preparation of lipid nanoparticles: an updated review
Stefanov, S., Gugleva, V., & Andonova, V. (2023) · Pharmacia · doi:10.3897/pharmacia.70.e108119 · Cited by 17
The nanocarrier strategy for crossing the blood-brain barrier in glioma therapy
Wu, H., Wang, Y., Ren, Z., Cong, H., Shen, Y., & Yu, B. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.109996 · Cited by 20
Margari, A., Monteduro, A. G., Rizzato, S., Capobianco, L., Crestini, A., Rivabene, R., Piscopo, P., D’Onofrio, M., Manzini, V., Trapani, G., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091827 · Cited by 14
“SLNs have been used as delivery systems to cross the BBB when intravenously injected and therefore represent an opportunity for ND treatment [34,35].”
BackgroundMethodHarisa, G. I., Sherif, A. Y., Alanazi, F. K., Ali, E. A., Omran, G. A., Nasr, F. A., Attia, S. M., & Alqahtani, A. S. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113148 · Cited by 16
The battle of lipid-based nanocarriers against blood-brain barrier: a critical review
Abla, K. K., & Mehanna, M. M. (2023) · Journal of drug targeting · doi:10.1080/1061186x.2023.2247583 · Cited by 19
“Additionally, outfitting lipid nanovehicles with hydrophilic polymers, in particular, polyethylene glycol (Peg) forms stealth nanocarriers which are able to escape ReS and avoid opsonisation [92].”
BackgroundNanoparticle-Based Drug Delivery for Vascular Applications
Naskar, A., Kilari, S., Baranwal, G., Kane, J., & Misra, S. (2024) · Bioengineering · doi:10.3390/bioengineering11121222 · Cited by 19
Metadata
- Authors
- Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H.
- Affiliations
- Taipei Medical University (TW)
- Cathay General Hospital (TW)
- Taipei Medical University Hospital (TW)
- Birla Institute of Technology and Science, Pilani (IN)
- Corresponding author
- Yang, Chih-Hao
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-07-31
- Volume
- 13
- Issue
- 8
- Pages
- 1183
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC8402065
- OpenAlex
- W3187770666
- Cited by
- 318
- References
- 268
- Citations by year
- 2026: 64 · 2025: 95 · 2024: 70 · 2023: 55 · 2022: 30 · 2021: 4
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-08-27)
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Science and Technology, Taiwan (MOST-106-2320-B-038-049-MY3, MOST-108-2314-B-038-022)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- solid lipid nanoparticles, blood-brain barrier, brain drug delivery, central nervous system disorders, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, brain tumors, epilepsy, ischemic stroke, nanoparticle synthesis, drug carriers, controlled drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.